Table 1 GWAS results of the four different analyses
Phenotype | SNP | CHR | BP | EA | OA | EAF | OR | SE | PVAL | Function | Gene/Nearest genes |
|---|---|---|---|---|---|---|---|---|---|---|---|
Seroconversion - One dose | rs9275109 | 6 | 32,649,676 | T | G | 0.61 | 0.86 | 0.01 | 1.1e−26 | intergenic | HLA-DQB1 - MTCO3P1 |
Seroconversion - One dose | rs79510369 | 2 | 160,858,048 | T | A | 0.01 | 1.48 | 0.06 | 5.3e−10 | intronic | PLA2R1 |
Seroconversion - Two dose | rs68033958 | 6 | 32,634,226 | A | G | 0.16 | 0.82 | 0.02 | 1.4e−21 | intronic | HLA-DQB1 |
Seroconversion - Two dose | rs3094055 | 6 | 30,332,146 | G | C | 0.77 | 0.89 | 0.02 | 2.1e−10 | upstream | UBQLN1P1 |
Breakthrough susceptibility | rs73062389 | 3 | 45,835,417 | A | G | 0.06 | 1.22 | 0.01 | 4.0e-56 | intronic | SLC6A20 |
Breakthrough susceptibility | rs16861415 | 3 | 186,696,364 | C | T | 0.08 | 0.84 | 0.01 | 6.8e-55 | intronic | ST6GAL1 |
Breakthrough susceptibility | rs11673136 | 19 | 9,007,748 | G | A | 0.48 | 1.08 | 0.01 | 4.6e-34 | intronic | MUC16 |
Breakthrough susceptibility | rs112313064 | 19 | 5,831,724 | C | T | 0.36 | 1.06 | 0.01 | 1.1e-22 | exonic | FUT6 |
Breakthrough susceptibility | rs681343 | 19 | 49,206,462 | T | C | 0.50 | 0.95 | 0.01 | 1.4e−17 | exonic | FUT2 |
Breakthrough susceptibility | rs1977829 | 10 | 111,975,041 | A | G | 0.18 | 0.94 | 0.01 | 1.4e−12 | intronic | MXI1 |
Breakthrough susceptibility | rs2550250 | 3 | 195,500,549 | T | C | 0.44 | 1.05 | 0.01 | 1.8e−12 | intronic | MUC4 |
Breakthrough susceptibility | rs6676150 | 1 | 155,123,837 | C | G | 0.39 | 1.04 | 0.01 | 2.7e−12 | intergenic | HMGN2P18 - KRTCAP2 |
Breakthrough susceptibility | rs17347644 | 3 | 101,547,733 | T | C | 0.35 | 0.96 | 0.01 | 1.3e-10 | intronic | NFKBIZ |
Breakthrough susceptibility | rs5117 | 19 | 45,418,790 | C | T | 0.24 | 0.96 | 0.01 | 4.7e-09 | intronic | APOC1 |
Breakthrough severity | rs429358 | 19 | 45,411,941 | C | T | 0.15 | 1.21 | 0.03 | 1.1e-08 | exonic | APOE |
